PMID- 27616592
OWN - NLM
STAT- MEDLINE
DCOM- 20180621
LR  - 20190221
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Sep 12
TI  - Emerging integrated nanoclay-facilitated drug delivery system for papillary 
      thyroid cancer therapy.
PG  - 33335
LID - 10.1038/srep33335 [doi]
LID - 33335
AB  - Nanoclay can be incorporated into emerging dual functional drug delivery systems 
      (DDSs) to promote efficiency in drug delivery and reduce the toxicity of 
      doxorubicin (DOX) used for thyroid cancer treatment. This paper reports the 
      expansion of the basal spacing of kaolinite nanoclay was expanded from 0.72 nm to 
      0.85 nm, which could provide sufficiently spacious site for hosting doxorubicin 
      molecules and controlling the diffusion rate. A targeted design for papillary 
      thyroid cancer cells was achieved by introducing KI, which is consumed by the 
      sodium-iodide symporter (NIS). As indicated by MTT assays, confocal laser 
      scanning microscopy and bio-TEM observations, methoxy-intercalated kaolinite 
      (KaolinMeOH) exhibited negligible cytotoxicity against papillary thyroid cancer 
      cells. By contrast, DOX-KaolinMeOH showed dose-dependent therapeutic effects in 
      vitro, and KI@DOX-KaolinMeOH was found to act as a powerful targeted therapeutic 
      drug. Furthermore, active and passive targeting strategies played a role in the 
      accumulation of the drug molecules, as verified by an in vivo bio-distribution 
      analysis.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Centre for Mineral Materials, School of Minerals Processing and Bioengineering, 
      Central South University, Changsha 410083, China.
FAU - Long, Mei
AU  - Long M
AD  - Centre for Mineral Materials, School of Minerals Processing and Bioengineering, 
      Central South University, Changsha 410083, China.
FAU - Huang, Peng
AU  - Huang P
AD  - Xiangya Hospital, Central South University, Changsha 410078, China.
FAU - Yang, Huaming
AU  - Yang H
AD  - Centre for Mineral Materials, School of Minerals Processing and Bioengineering, 
      Central South University, Changsha 410083, China.
AD  - Hunan Key Lab of Mineral Materials and Application, Central South University, 
      Changsha 410083, China.
AD  - State Key Lab of Powder Metallurgy, Central South University, Changsha 410083, 
      China.
FAU - Chang, Shi
AU  - Chang S
AD  - Xiangya Hospital, Central South University, Changsha 410078, China.
FAU - Hu, Yuehua
AU  - Hu Y
AD  - Centre for Mineral Materials, School of Minerals Processing and Bioengineering, 
      Central South University, Changsha 410083, China.
AD  - Hunan Key Lab of Mineral Materials and Application, Central South University, 
      Changsha 410083, China.
FAU - Tang, Aidong
AU  - Tang A
AD  - School of Chemistry and Chemical Engineering, Central South University, Changsha 
      410083, China.
FAU - Mao, Linfeng
AU  - Mao L
AD  - Xiangya Hospital, Central South University, Changsha 410078, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160912
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Drug Carriers)
RN  - 24H4NWX5CO (Kaolin)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/*administration & dosage/pharmacokinetics/toxicity
MH  - Carcinoma, Papillary/*drug therapy
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Doxorubicin/*administration & dosage/pharmacokinetics/toxicity
MH  - Drug Carriers/*administration & dosage/pharmacokinetics/toxicity
MH  - Drug Screening Assays, Antitumor
MH  - Female
MH  - Humans
MH  - Kaolin/*administration & dosage/pharmacokinetics/toxicity
MH  - Nanostructures/toxicity
MH  - Rabbits
MH  - Swine
MH  - Swine, Miniature
MH  - Thyroid Cancer, Papillary
MH  - Thyroid Neoplasms/*drug therapy
MH  - Tissue Distribution
PMC - PMC5018840
EDAT- 2016/09/13 06:00
MHDA- 2018/06/22 06:00
PMCR- 2016/09/12
CRDT- 2016/09/13 06:00
PHST- 2016/06/15 00:00 [received]
PHST- 2016/08/25 00:00 [accepted]
PHST- 2016/09/13 06:00 [entrez]
PHST- 2016/09/13 06:00 [pubmed]
PHST- 2018/06/22 06:00 [medline]
PHST- 2016/09/12 00:00 [pmc-release]
AID - srep33335 [pii]
AID - 10.1038/srep33335 [doi]
PST - epublish
SO  - Sci Rep. 2016 Sep 12;6:33335. doi: 10.1038/srep33335.